Effects of adding behavioral treatment to opioid detoxification with buprenorphine.

Bickel, Warren K.; Amass, Leslie; Higgins, Stephen T.; Badger, Gary J.; Esch, Rebecca A.

doi:10.1037/0022-006x.65.5.803

Cited by 175 publications

(116 citation statements)

References 30 publications

Supporting

Mentioning

108

Contrasting

Unclassified

Order By: Relevance

“…Rewards may take multiple forms, but the most common include vouchers that may be exchanged for goods or services, prizes, or the granting of some form of privilege. Contingency management approaches have been shown to improve retention and to increase abstinence with various substance-abusing populations, including those dependent on cocaine (Higgins et al, 1994), marijuana (Budney, Higgins, Radonovich, & Novy, 2000), alcohol (Petry, Martin, Cooney, & Kranzler, 2000), and opioids (Bickel, Amass, Higgins, Badger, & Esch, 1997;Silverman, Chutuape, Bigelow, & Stitzer, 1996).…”

Section: Voucher-based Motivational Incentivesmentioning

confidence: 99%

Innovation adoption in substance abuse treatment: Exposure, trialability, and the Clinical Trials Network

Ducharme

Knudsen

Roman

et al. 2007

Journal of Substance Abuse Treatment

103

151

View full text Add to dashboard Cite

Researchers and policymakers are increasingly focusing on factors that facilitate or impede the diffusion of evidence-based treatment techniques into routine clinical practice. One potentially fruitful avenue of research is the influence of involvement in research networks as a predictor of organizational innovation. The Clinical Trials Network (CTN) is examining a number of behavioral and pharmacological treatment techniques in controlled multisite studies. Using data from participating CTN treatment programs and large samples of programs outside the CTN, these analyses examine the influence of exposure to clinical trials on the subsequent adoption of buprenorphine and voucher-based motivational incentives. The analyses show that, controlling for a variety of organizational characteristics, direct exposure to buprenorphine clinical trials in the CTN significantly increased the odds of subsequent adoption. By contrast, the adoption of motivational incentives was entirely explained by organizational characteristics. The findings suggest that adoption of treatment innovations is a function of exposure, organizational resources, nature of innovations, and stage of the diffusion process.

show abstract

Section: Voucher-based Motivational Incentivesmentioning

confidence: 99%

Innovation adoption in substance abuse treatment: Exposure, trialability, and the Clinical Trials Network

Ducharme

Knudsen

Roman

et al. 2007

Journal of Substance Abuse Treatment

103

151

View full text Add to dashboard Cite

show abstract

“…Voucher-based incentives have been shown to be effective in improving retention and abstinence in outpatient opioid detoxification (26), in reducing smoking as well as illicit substance use among opioid addicts in a methadone maintenance program (27), in reducing the frequency of marijuana use (28), and in improving medication compliance among opioid-dependent individuals treated with naltrexone maintenance (29-31). Iguchi et al (32) expanded voucher-based contingency management to outcomes other than drug-negative urine specimens, demonstrating that reinforcement of tasks outlined in an individualized, verifiable treatment plan was associated with greater reductions in illicit drug use than reinforcement of drug-free urine specimens.…”

Section: Contingency Management Therapiesmentioning

confidence: 99%

Behavioral Therapies for Drug Abuse

Carroll

Onken

2007

FOC

View full text Add to dashboard Cite

The past three decades have been marked by tremendous progress in behavioral therapies for drug abuse and dependence, as well as advances in the conceptualization of approaches to development of behavioral therapies. Cognitive behavior therapy, contingency management, couples and family therapy, and a variety of other types of behavioral treatment have been shown to be potent interventions for several forms of drug addiction, and scientific progress has also been greatly facilitated by the articulation of a systematic approach to the development, evaluation, and dissemination of behavioral therapies. The authors review recent progress in strategies for the development of behavioral therapies for drug and alcohol abuse and dependence and discuss the range of effective behavioral therapies that are currently available.Before the advent of research on treatments derived from operant and classic behaviorism, there was little indication that any form of psychosocial treatment was effective for any type of mental disorder (1-3). Research on behavioral therapies flourished with the adoption of the technology model (4, 5), which sought to systematize these therapies and the experimental methods through which they could be evaluated to achieve a level of methodological rigor on a par with the standards for pharmacological research (6,7). By the mid to late 1980s, there were a number of behavioral treatments that had been shown to be efficacious in the treatment of a variety of mental disorders, including depressive, panic, and obsessive-compulsive disorders. However, the methodological rigor and specificity that were characteristic of these studies were not yet apparent in drug abuse treatment studies, with a few exceptions (8). Although behavioral approaches were universally available in drug abuse treatment programs by the late 1980s (9), there was continued pessimism in the field regarding the efficacy of behavioral therapies for drug use disorders (10, 11).In the early 1990s, studies in which behavioral therapies, therapist training, study populations, and objective outcome measures were carefully specified and in which participants were randomly assigned to experimental and control or comparison conditions began to appear more frequently in the drug abuse treatment literature. The technology model facilitated the identification of effective behavioral treatments for substance use disorders as it enhanced the internal validity and replicability of research on behavioral therapies. However, the technology model also had the unanticipated effect of restricting the development of novel therapies. The stringent methodological requirements associated with the technology model (e.g., requiring investigators to have fully developed treatment manuals, therapist training protocols, and fidelity rating procedures) limited the therapies eligible for efficacy evaluation to those already developed for drug abuse and to those which could easily be adapted from other areas (e.g., alcohol and depression treatments). This res...

show abstract

“…Most clients regularly used at least two drugs, typically heroin or buprenorphine and a benzodiazepine. Another study of a 13-week detoxification program using buprenorphine and behavioral therapy reported that 89% tested positive for benzodiazapenes and 63% for cocaine at least once during the program (Bickel, Amass, Higgins, Badger, & Esch, 1997).…”

Section: Buprenorphinementioning

confidence: 99%

Buprenorphine: “Field Trials” of a New Drug

Agar¹,

French

Murdoch

2001

Qual Health Res

View full text Add to dashboard Cite

Buprenorphine is being introduced as a new treatment drug for narcotics addiction in the United States. The authors were asked by the National Institute on Drug Abuse to conduct a field trial to determine if buprenorphine might play a role in street markets. Because no street use of the drug existed in the United States, the authors used three sources of information: (a) “street readings” of clinical studies, (b) Internet discussion lists, and (c) research in other countries. By using an emergent style of analysis that relies on replication of patterns across disparate data sources, it was determined that buprenorphine has desirable characteristics from a street addict point of view. An evaluation of the field trial 5 years later evaluates its accuracy.

show abstract

Effects of adding behavioral treatment to opioid detoxification with buprenorphine.

Cited by 175 publications

References 30 publications

Innovation adoption in substance abuse treatment: Exposure, trialability, and the Clinical Trials Network

Innovation adoption in substance abuse treatment: Exposure, trialability, and the Clinical Trials Network

Behavioral Therapies for Drug Abuse

Buprenorphine: “Field Trials” of a New Drug

Contact Info

Product

Resources

About